---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000442"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:53:21.378449+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Medical beats FY22 revenue guidance; Q4 revenue up ~47-48% YoY

## Summary
- Preliminary Q4 2022 revenue $49.1M-$49.6M, up 47-48% YoY.
- Preliminary FY22 revenue $141.2M-$141.7M, up ~50% YoY, above prior guidance of $135M-$138M.
- CEO cites strength of direct sales channel, DTC programs, and R&D investments.
- Company plans to provide 2023 guidance on Q4 earnings call.

## SEC filing metadata
- accession: 0000950170-23-000442
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017023000442/0000950170-23-000442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017023000442/tmci-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000442
- JSON: https://secwatch.observer/filing/0000950170-23-000442.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000442.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported fourth quarter and full year 2022 results: revenue $49.1 to $49.6 million and $141.2 to $141.7 million, respectively.
  - Period: fourth quarter and full year 2022
  - Revenue: $49.1 to $49.6 million and $141.2 to $141.7 million, respectively
  - Result: preliminary results
  source text: preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively. The full
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023000442/0000950170-23-000442-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.